Neutrophils and their role in lung cancer treatment response
Neutrophil derived proteinases abolish the IFNG signature in NSCLC
['FUNDING_R01'] · FRED HUTCHINSON CANCER CENTER · NIH-10884281
This study is looking at how certain white blood cells called neutrophils might make it harder for cancer treatments, known as immune checkpoint inhibitors, to work well in people with non-small cell lung cancer, and the researchers hope to find ways to improve these treatments by understanding how neutrophils affect the immune response to tumors.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | FRED HUTCHINSON CANCER CENTER (nih funded) |
| Locations | 1 site (SEATTLE, UNITED STATES) |
| Trial ID | NIH-10884281 on ClinicalTrials.gov |
What this research studies
This research investigates how neutrophils in non-small cell lung cancer (NSCLC) may hinder the effectiveness of immune checkpoint inhibitors, which are treatments that help the immune system fight cancer. The researchers will explore how proteins released by neutrophils can degrade important signals that attract immune cells to tumors, potentially preventing a strong immune response. By using advanced models that mimic tumor environments, they aim to understand the mechanisms behind this process and identify new targets for improving treatment outcomes for patients with NSCLC.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with non-small cell lung cancer who are considering or currently undergoing immune checkpoint inhibitor therapy.
Not a fit: Patients with other types of lung cancer or those who are not eligible for immunotherapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment strategies for NSCLC patients, enhancing their response to immunotherapy.
How similar studies have performed: Previous research has shown that targeting immune cell interactions in tumors can improve treatment responses, suggesting that this approach may also yield significant insights.
Where this research is happening
SEATTLE, UNITED STATES
- FRED HUTCHINSON CANCER CENTER — SEATTLE, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: HOUGHTON, A MCGARRY — FRED HUTCHINSON CANCER CENTER
- Study coordinator: HOUGHTON, A MCGARRY
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.